Dr. Andre Goy on Crizotinib for ALK-positive Pediatric Patients With ALCL

Andre Goy, MD, MS, chief, Lymphoma Division, chairman, John Theurer Cancer Center at Hackensack University Medical Center, discusses a small phase I trial that used crizotinib (Xalkori) to treat ALK-positive pediatric patients with anaplastic large cell lymphoma (ALCL), neuroblastoma, and inflammatory myofibroblastic tumors (IMTs).

View more at http://www.onclive.com/confere....nce-coverage/asco-20

• categorie